CDK4 and lung carcinoma: An additional number of microRNAs (miR-124a, miR9, miR200b and miR-106b) were shown to mediate cellular response to CDK4/6 inhibitors in acute lymphoblastic leukemia, breast and lung cancer cells, without, however, affecting sensitivity to treatment (Table 3).